FOLH1 and prostate carcinoma: This system demonstrated excellent stability, controlled drug release, and high PSMA specificity, integrating therapy, fluorescence imaging, and nuclear tracking into a single platform for precise and visible prostate cancer treatment (Fig. 8B) [242].